logo
Plus   Neg
Share
Email

Zogenix Plunges After FDA Refuses To Review Seizure Drug

Shares of Zogenix Inc. (ZGNX) plunged in the Monday after-hours trade, following announced that the company received a Refusal to File letter from the U.S. Food and Drug Administration regarding its New Drug Application for FINTEPLA or ZX008, fenfluramine hydrochloride for the treatment of seizures associated with Dravet syndrome.

Upon its preliminary review, the FDA determined that the NDA, submitted on February 5, 2019, was not sufficiently complete to permit a substantive review. In the letter, the FDA cited two reasons for the RTF decision: first, certain non-clinical studies were not submitted to allow assessment of the chronic administration of fenfluramine; and, second, the application contained an incorrect version of a clinical dataset, which prevented the completion of the review process that is necessary to support the filing of the NDA. The FDA has not requested or recommended additional clinical efficacy or safety studies.

The company said it will seek immediate guidance, including a Type A meeting with the FDA, to clarify and respond to the issues identified in the Refusal to File letter.

Zogenix noted that its Marketing Authorization Application for FINTEPLA for the treatment of seizures associated with Dravet syndrome was previously accepted for review by the European Medicines Agency, and the Company anticipates an approvability decision could be reached by the European Medicines Agency in the first quarter of 2020.

ZGNX closed Monday regular trading at $51.85, down $0.15 or 0.29 percent. In the after hours trade, the stock further dropped $16.35 or 31.53%.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Polaris Industries Inc. is recalling certain Ranger and General Utility, as well as All-Terrain vehicles citing risks of crash, the U.S. Consumer Product Safety Commission said in a statement. The Medina, Minnesota-based company has called back about 26,730 units of Model Year 2019 - 2020 Ranger XP 1000 & Model Year 2020 General XP 1000 Utility vehicles. Gilead Sciences Inc. (GILD) said Friday that the European Commission has granted conditional marketing authorization for Veklury or remdesivir as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19. FedEx is asking NFL team Washington Redskins to change its name for its racist connotations. The delivery services company, which is a major sponsor for the team, made the suggestion following increasing pressure from its investors amid the ongoing protests against racial injustice and inequality that arose from the killing of African-American George Floyd.
Follow RTT